Jamunarani Veeraraghavan

Baylor College of Medicine — United States

Medicine · Health Sciences

24h-index2.2kcitations191works0.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

HER2/EGFR in Cancer Research(101), Lung Cancer Treatments and Mutations(52), Advanced Breast Cancer Therapies(50), Monoclonal and Polyclonal Antibodies Research(36), Chronic Lymphocytic Leukemia Research(22)

Publications191 total

Abstract PS5-01-19: Mechanisms of resistance to anti-HER2 therapies in brain metastatic derivatives of inflammatory HER2-positive breast cancer models
Clinical Cancer Research·2026
Abstract PS2-11-13: Resistance to tucatinib associated with hyperactive EGFR could be overcome by co-targeting HER2 and EGFR in HER2-positive breast cancer models
Clinical Cancer Research·2026
Figure S4 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
2025Open Access
Figure S6 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
2025Open Access
Figure S3 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
2025Open Access
Figure S2 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
2025Open Access
Supplementary Tables 1 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
2025Open Access
Figure S1 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
2025Open Access
Figure S5 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
2025Open Access
Detection of heterogeneous resistance mechanisms to tyrosine kinase inhibitors from cell-free DNA
Cell Genomics·2025Open Access
Abstract P3-04-27: Resistance to neratinib in HER2+ breast cancer: Mechanistic insights and treatment approaches
Clinical Cancer Research·2025
Interactions between ADGRF1 (GPR110) and extracellular matrix proteins govern its effects on tumorigenesis in HER2‐positive breast cancer
British Journal of Pharmacology·2025· 5 citedOpen Access
HER2-Positive Breast Cancer Treatment and Resistance
Advances in experimental medicine and biology·2025· 7 cited
Figure S2 from A multiparameter molecular classifier to predict response to neoadjuvant lapatinib plus trastuzumab without chemotherapy in HER2+ breast cancer
2024Open Access
Figure S3 from A multiparameter molecular classifier to predict response to neoadjuvant lapatinib plus trastuzumab without chemotherapy in HER2+ breast cancer
2024Open Access
Supplementary Tables 1 from A multiparameter molecular classifier to predict response to neoadjuvant lapatinib plus trastuzumab without chemotherapy in HER2+ breast cancer
2024Open Access
Figure S2 from A multiparameter molecular classifier to predict response to neoadjuvant lapatinib plus trastuzumab without chemotherapy in HER2+ breast cancer
2024Open Access
Figure S1 from A multiparameter molecular classifier to predict response to neoadjuvant lapatinib plus trastuzumab without chemotherapy in HER2+ breast cancer
2024Open Access
Figure S6 from A multiparameter molecular classifier to predict response to neoadjuvant lapatinib plus trastuzumab without chemotherapy in HER2+ breast cancer
2024Open Access
Data from A multiparameter molecular classifier to predict response to neoadjuvant lapatinib plus trastuzumab without chemotherapy in HER2+ breast cancer
2024Open Access
page 1 of 10Next →

Frequent Co-authors

Rachel Schiff(37), Mothaffar F. Rimawi(25), Carmine De Angelis(20), C. Kent Osborne(17), Susan G. Hilsenbeck(15), Sarmistha Nanda(14), Jorge S. Reis‐Filho(13), Vidyalakshmi Sethunath(12), Carolina Gutiérrez(12), Lanfang Qin(11), Britta Weigelt(11), Natarajan Aravindan(11), Martin J. Shea(10), Terence S. Herman(10), Aleix Prat(9), Xiaoyong Fu(9), Tao Wang(9), Tamika Mitchell(9), Mohan Natarajan(9), Agostina Nardone(8)